About MediWound Ltd. (MDWD)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MDWD Key Statistics
| Current Price | $17.03 | Market Cap | $216 million |
|---|---|---|---|
| Daily Change | -2.41% | Volume | 35K |
| 52-Week High | $22.51 | 52-Week Low | $14.14 |
| Sector | Healthcare | Industry | Biotechnology |
MDWD Price Performance
MediWound Ltd. stock has returned -0.85% over the past day, -0.40% over the past week, +1.87% over the past month, and +5.76% over the past three months. The stock trades between a 52-week low of $14.14 and a high of $22.51.